US 10,363,298 B2
Immunomodulatory compounds
Garry Taylor, St. Andrews (GB); and Helen Connaris, St. Andrews (GB)
Assigned to University Court of the University of St. Andrews, (GB)
Appl. No. 15/113,672
Filed by University Court of the University of St Andrews, St. Andrews (GB)
PCT Filed Jan. 23, 2015, PCT No. PCT/GB2015/050161
§ 371(c)(1), (2) Date Jul. 22, 2016,
PCT Pub. No. WO2015/110831, PCT Pub. Date Jul. 30, 2015.
Claims priority of application No. 1401228.0 (GB), filed on Jan. 24, 2014; and application No. 1405306.0 (GB), filed on Mar. 25, 2014.
Prior Publication US 2017/0007692 A1, Jan. 12, 2017
Int. Cl. A61K 39/07 (2006.01); A61K 39/09 (2006.01); A61K 39/104 (2006.01); A61K 39/39 (2006.01); A61K 38/16 (2006.01); A61K 39/02 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/107 (2013.01) [A61K 38/16 (2013.01); A61K 39/092 (2013.01); A61K 39/104 (2013.01); A61K 39/39 (2013.01); G01N 33/6854 (2013.01); A61K 2039/543 (2013.01); A61K 2039/572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/58 (2013.01); C12N 2760/16171 (2013.01); G01N 2333/11 (2013.01); G01N 2333/115 (2013.01); G01N 2333/21 (2013.01); G01N 2400/00 (2013.01); G01N 2500/04 (2013.01)] 2 Claims
 
1. A method of modulating or priming an immune response in a subject, the method comprising administering an immunomodulatory amount or quantity of Sp2CBMTD to a healthy subject in need thereof in more than one dose prior to an infection or a likely infection caused or contributed to by a pathogen.